study comparing the effects of Esomeprazole adminstered orally and intravenously on basal and pentrigastrin-stimulated acid output in subjects with symptoms of Gastroesophageal reflux disease (GERD)

Study identifier:D9615C00013

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An open, randomised two way crossover study comparing the effects of 40mg of Esomeprazole adminstered orally and intravenously as a 3 minute injection on basal and pentrigastrin-stimulated acid output in subjects with symptoms of Gastroesophageal reflux disease (GERD)

Medical condition

Gastroesophageal reflux disease (GERD)

Phase

Phase 4

Healthy volunteers

No

Study drug

Esomeprazole

Sex

All

Actual Enrollment

60

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 01 Sept 2002
Primary Completion Date: 01 Nov 2002
Study Completion Date: 01 Nov 2002

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria